Richardcyoung.com

The Online Home of Author and Investor, Dick Young

  • Home
  • How We Are Different
  • Debbie Young
  • About Us
    • Foundation Principles
    • Contributors
  • Investing
    • You’ve Read The Last Issue of Intelligence Report, Now What?
  • Your Survival Guy
  • The Great Reset
  • COVID-19
  • My Rifles
  • Dividends and Compounding
  • Your Security
  • The Swiss Way
  • Dick Young
  • Key West
  • Paris
  • Dick’s R&B Top 100
  • Liberty & Freedom Map
  • Bank Credit & Money
  • Your Survival Guy’s Super States
  • NNT & Cholesterol
  • Work to Make Money/Invest to Save Money
  • Your Health
  • Ron Paul
  • US Treasury Yield Curve: My Favorite Investor Tool

Statin Drugs/NNT Alert

July 19, 2022 By Richard C. Young

By roger ashford @ Shutterstock.com

UPDATE July 19, 2022: In the UK Express, Solen Le Net highlights some of the undesirable side effects of statin drugs, writing:

High cholesterol contributes to the furring of the arteries which leads to heart attacks and other major cardiac events. Fortunately, statins prevent the deposit of fatty molecules inside arteries. In some cases, however, unsteadiness in walking has been reported among patients.

Compliance with statin therapy has remained problematic due to the drug’s undesirable side effects.

Myopathy is estimated to occur in 0.5 percent of patients treated with statins during clinical trials, and Rhabdomyolysis in an even smaller portion of users.

Fewer studies have evaluated muscle strength among users, however, so the incidence of weakness, whether related to myopathy or not, may be under-appreciated.

In one study, researchers assessed several patients for proximal muscle weakness after finding they developed proximal weakness with a decline in walking, which reversed after discontinuing the drug.

Writing in the journal of Neuro-rehabilitation and Neural Repair, the authors said: “Unsteadiness in walking, especially on an uneven surface or on changing direction, was the most common complaint.

“[The patients] usually could not pinpoint the onset, but their history of daily activity suggested function changes by six months after the first use of a statin.

“The patients and their physicians did not suspect muscle weakness. They attributed the symptoms to complications of chronic or recent neurological disorders.”

Originally posted April 25, 2014.

If you have been prescribed a statin drug, you will benefit greatly by reading the research presented here, here and here. The concept of NNT, or number needed to treat, offers compelling insight for every patient regardless of the prescribed drug or disease in question.

The harms of statins are less publicized than benefits, but are well documented. A recent narrative review of statin myopathy suggests that 10% is a relatively conservative estimate for this side effect,1 which may be a primary contributor to high rates of drug discontinuation.2 An additional, more concerning side effect is statin-induced diabetes, as noted in the JUPITER study and a large Women’s Health Initiative cohort, studies that best represent primary prevention cohorts.3 We use an absolute risk estimate for statin-induced diabetes with the understanding that this may underestimate risk for many. Baseline risk of diabetes is likely the greatest driver of risk for statin-induced diabetes, and the JUPITER trial enrolled patients at lower risk (2.4%) than many, perhaps most, patients who take statins. Our calculation presumes this low baseline risk and that the aggregate chance of diabetes is time-dependent and linear. We have thus extrapolated from the 1.9-year trial data to a 5-year endpoint, the same time endpoint and calculation used for benefits. These data are relevant to new onset diabetes only, and do not address the equally concerning possibility that some diabetic patients may experience statin-induced worsening of their disease, or inability to manage or cure their disease using lifestyle changes. We look forward to data addressing these issues.

Our sense, based on factors noted above, is that the benefits of these drugs are likely exaggerated partly by an unconscious ‘hope bias’ on the part of readers and authors. This is common in the early literature on therapeutic innovations, and is often attenuated as further literature emerges. In addition, post-marketing surveillance data is in its early stages with this class of drugs and preliminary reports suggest that cognitive decline, tendonopathies, and other side effects may emerge in future literature. Finally, the source of the great majority of these data is industry, which has a spotty history of integrity in trial data reporting, suggesting these data to be a best-case scenario.

Related video:

If you’re willing to fight for Main Street America, click here to sign up for my free weekly email.

Related Posts

  • Statin Drugs: Part 1
  • Statin Drugs: Part 2
  • Statin Drugs: Part 3
  • Author
  • Recent Posts
Richard C. Young
Richard C. Young
Richard C. Young is the editor of Young's World Money Forecast, and a contributing editor to both Richardcyoung.com and Youngresearch.com.
Richard C. Young
Latest posts by Richard C. Young (see all)
  • Biden’s Fake Democracy Summit: Hungary and Turkey Snubbed - March 24, 2023
  • DONBAS: Russian Tanks Face Gauntlet of Death from Javelin Wielding Ukrainians - March 24, 2023
  • Do You Know How to Slow Your Brain’s Aging? - March 24, 2023

Dick Young’s Must Reads

  • Biden Wants to Gut the Tax Benefit of 401K Plans
  • TROJAN HORSE: “Diversity, Equity, and Inclusion” is Critical Race Theory in Disguise
  • V4 Stands Against North African and Middle Eastern Invasion
  • Warning! Your Survival Guy’s on a Boil Water Advisory
  • Your Best State on Guns, Plus the 8th Wonder of the World
  • Work to Make Money/Invest to Save Money
  • The Claremont Institute: Protecting the American Way of Life
  • Richard Feynman Solved the Space Shuttle Disaster Mystery
  • Can Curcumin Help in Fighting Cancer?
  • America’s Silent Army with 423M Guns

Disclosure

RSS Youngresearch.com

  • If You’re a Highly Effective Person, We Should Talk
  • Trouble Now Brewing at Deutsche Bank
  • Is Vanguard Voting Against Your Political Beliefs?
  • Are 0DTE Options a Threat to Markets?
  • “I Need Preservation of Principal and Growth”
  • Are You Fairly Wealthy? I’m Listening
  • Treasury Studying How to Increase Deposit Insurance
  • Your Survival Guy’s BEST Insider’s Guide to Key West
  • For Whom Is Your Portfolio Serving?
  • Who’s to Blame for Banking Vulnerability?

RSS Yoursurvivalguy.com

  • If You’re a Highly Effective Person, We Should Talk
  • What’s Happening to Charles Schwab?
  • Prepare for the Predictable
  • Is Vanguard Voting Against Your Political Beliefs?
  • Call It the Difference between Normal and Crazy
  • “I Need Preservation of Principal and Growth”
  • DEMOCRATIC SENATOR: Biden’s ESG Veto “Absolutely Infuriating”
  • Are You Fairly Wealthy? I’m Listening
  • How Long Is Your Water Supply Chain?
  • Your Survival Guy’s BEST Insider’s Guide to Key West

Biden’s Fake Democracy Summit: Hungary and Turkey Snubbed

Freefalling at Stanford

If You’re a Highly Effective Person, We Should Talk

DONBAS: Russian Tanks Face Gauntlet of Death from Javelin Wielding Ukrainians

Do You Know How to Slow Your Brain’s Aging?

We’ll Burn the Place Down!

Copyright © 2023 | Terms & Conditions | About Us | Dick Young | Archives